Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage
biopharmaceutical company focused on preventing and treating an
immune hyper-response called ‘cytokine storm,’ announced today that
management will present and participate at several events in March
with investors, analysts, bankers and potential partners. The goal
of the events is to update participants regarding the company’s
progress in developing lenzilumab for COVID-19 as well as
additional indications. The mix of in person and virtual events is
intended to reach the broadest possible audience.
Details of the events:
Credit Suisse 2022 London Global
Healthcare Conference
Date: March 1-2, 2022 Location: Virtual, London Time: 8:00-17:45
GMT Presenter: Dale Chappell, MD, Chief Scientific Officer
Information: amanda.baird@credit-suisse.com
Oppenheimer March Thought Leadership
Series
Date: March 4, 2022 Location: Virtual, New York City Time: 9:00
AM EST Presenters: Cameron Durrant, CEO, Dale Chappell, CSO,
Timothy Morris, COO/CFO Information: deena.sullivan@opco.com
34th Annual Roth Conference
Date: March 13-15, 2022 Location: Dana Point, CA Presentation:
Pre-recorded presentations will be available ahead of the
conference Fireside chat: Tuesday, March 15, 2022, 9:00 PST
Participant: Timothy Morris COO/CFO Webcast:
https://wsw.com/webcast/roth43/hgen/1810184
Oppenheimer 32nd Annual Healthcare
Conference
Date: March 15-16, 2022 Location: Virtual, New York City
Presentation date: March 16, 2022 Presentation time: 9:20 AM EST
Participants: Cameron Durrant, CEO, Dale Chappell, CSO, Adrian
Kilcoyne, CMO, Timothy Morris COO/CFO Webcast link:
https://wsw.com/webcast/oppenheimer20/hgen/2746044
BIO-Europe Spring 2022
Date: March 28-31, 2022 Location: Virtual, Basel, Switzerland
Presentation: Available on demand Participants: Bob Atwill, Head of
Asia-Pacific Region, Timothy Morris COO/CFO Information:
www.informaconnect.com/bioeurope-spring
MedInvest Pharmaceutical and Biotechnology
Investor Conference
Date: March 28-April 1, 2022 Location: Virtual Presentation:
Available livestream and on-demand Participants: Cameron Durrant
CEO, Timothy Morris COO/CFO Information:
www.medinvestconferences.com
The presentation and webcast links used during the events will
be available on the Humanigen website at www.humanigen.com.
About Humanigen
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), is a
clinical-stage biopharmaceutical company focused on preventing and
treating an immune hyper-response called ‘cytokine storm.’
Lenzilumab is a first-in-class antibody that binds to and
neutralizes granulocyte-macrophage colony-stimulating factor
(GM-CSF). Humanigen is developing lenzilumab as a treatment for
cytokine storm associated with COVID-19 and CD19-targeted CAR-T
cell therapies and is also exploring the effectiveness of
lenzilumab in acute Graft versus Host Disease in patients
undergoing allogeneic hematopoietic stem cell transplantation. For
more information, visit www.humanigen.com and follow Humanigen on
LinkedIn, Twitter, and Facebook.
Forward-Looking Statements
All statements other than statements of historical facts
contained in this press release are forward-looking statements.
Forward-looking statements reflect management's current knowledge,
assumptions, judgment, and expectations regarding future
performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct, and
you should be aware that actual events or results may differ
materially from those contained in the forward- looking statements.
Words such as "will," "expect," "intend," "plan," "potential,"
"possible," "goals," "accelerate," "continue," and similar
expressions identify forward-looking statements, including, without
limitation, statements regarding our plans relating to
lenzilumab.
Forward-looking statements are subject to a number of risks and
uncertainties including, but not limited to, the risks inherent in
our lack of profitability and need for additional capital to grow
our business; our dependence on partners to further the development
of our product candidates; the uncertainties inherent in the
development, attainment of the requisite regulatory authorizations
and approvals and launch of any new pharmaceutical product; the
outcome of pending or future litigation; and the various risks and
uncertainties described in the "Risk Factors" sections of our
latest annual and quarterly reports and other filings with the
SEC.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You should not rely upon any
forward-looking statements as predictions of future events. We
undertake no obligation to revise or update any forward-looking
statements made in this press release to reflect events or
circumstances after the date hereof, to reflect new information or
the occurrence of unanticipated events, or to update the reasons
why actual results could differ materially from those anticipated
in the forward-looking statements, in each case, except as required
by law.
Source: Humanigen, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220225005112/en/
Humanigen Investor Relations Timothy E. Morris, COO & CFO
tmorris@humanigen.com +1 650-400-6874
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024